Search Results
SEARCH RESULTS
For TAME

TAME


As seen in a Ron Howard-directed National Geographic special and featured in TEDMED, the TODAY Show, Business Insider, WIRED, The Sunday Times, The New York Times, The Wall Street Journal, The Washington Post, CNN.com, The Sunday Times, and more, the Targeting Aging with Metformin (TAME) Trial shows promise for revolutionizing the way age-related diseases are treated.  AFAR shares these FAQs to help explain the momentum behind TAME. What is the TAME Trial? Targeting Aging with Metformin (TAME) is a novel clinical trial, that will test whether the…



Board Member in the News: Nir Barzilai gives TEDMED talk on Metformin and TAME Trial


On August 29, 2017, TEDMED published a blog and talk by 1997 Paul B. Beeson Emerging Leaders Career Development Award in Aging scholar, 1994 AFAR Research Grant recipient, and AFAR Deputy Scientific Director Nir Barzilai, MD. In the TEDMED talk, Can we grow older without growing sicker?, Dr. Barzilai explores the prevalence of age-related diseases, the diversity of longevity in centenarians, and how, if the FDA moves to consider aging an indication, drugs like Metformin and Rapamycin have the potential to target aging and extend years of health. He poses: “What if we spent 80 years to get to the biological age of 60?…



Board Members in the News: Nir Barzilai, Steve Austad, and Jay Olshansky on TAME trial in WIRED


On June 5, 2017, WIRED prominently spotlighted AFAR Deputy Scientific Director Nir Barzilai, MD and the AFAR-managed TAME trial. AFAR Scientific Director Steven N. Austand, PhD, and board member S. Jay Olshanksy, PhD, also lend insights. The feature story, Forget the Blood of Teens. This Pill Promises to Extend Life for a Nickel a Pop, describes the history of metformin, how the drug works inside our cells, and the state of moving metformin into clinical trials. The article details how the researchers behind the TAME Trial first prepared for their initial meetings FDA officials at a 2014 conference…



Board Member in the News: Nir Barzilai on the TAME trial in Wall Street Pit


On August 27, 2017, The Wall Street Pit featured 1997 Paul B. Beeson Emerging Leaders Career Development Award in Aging scholar, 1994 AFAR Research Grant recipient, and AFAR Deputy Scientific Director Nir Barzilai, MD. The article, A Potential Anti-Aging Pill Promises to Extend Life For 5 Cents a Pop, highlights the AFAR-managed TAME trial and the significant efficacy Metformin has proven in past studies.  The article also features Dr. Barzilai’s 2014 TEDTalk: How to die young at a very old age. Read the full Wall Street Pit article here. Nir Barzilai, MD is the Director of the Institute for Aging Research…



AFAR in the News: David Sinclair and Steve Austad on the TAME Trial on Discovery’s Seeker.com


On March 31, 2017, Discovery’s Seeker.com, which is dedicated to curiosity and innovation, featured AFAR Board Member and 2000 Research Grant recipient, David Sinclair, PhD, and Scientific Director, Steve Austad, PhD, in an article on the progress of the TAME (Targeting Aging with Metformin) Trial, which AFAR is helping manage. The article discusses the challenges in TAME’s goal of seeking FDA recognition of aging as a treatable medical condition. The FDA currently only approves drugs for specific “indications” or recognized medical conditions--of which aging is currently not classified as one. The


STAY CONNECTED